StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
MISTBullishCorporate Developmentsnews
High materiality7/10

Milestone Advances CARDAMYST Adoption as Insurer Coverage Expands

Aug 12, 2026, 7:16 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Near-term upside from payer coverage expansion (>50% insured) and Phase 3 AFib-RVR initiation; execution risk mitigated by cash runway into 2027. While current revenues are small, the combination of coverage depth and enrollment progress can re-rate risk/reward, especially if data or payer coverage momentum accelerates.

AI summary

What happened, with direct paths to the underlying reporting

Milestone reported solid uptake for CARDAMYST as insurer coverage surpassed 50% of commercially insured lives, signaling a meaningful addressable market. The Phase 3 AFib-RVR trial opened (ReVeRA-301) with first enrollment expected in 2H 2026, expanding etripamil's potential beyond PSVT. With $170.6 million cash and a runway into late 2027, near-term catalysts focus on payer adoption and clinical progress, while profitability remains distant.

  • CARDAMYST coverage now exceeds 50% of commercially insured lives. Uptake rising.
  • ReVeRA-301 AFib-RVR Phase 3 trial opened; first patient enrollment expected 2H 2026.
  • Cash, cash equivalents and short-term investments: $170.6M as of 6/30/2026; runway into 2H 2027.
  • Q2 2026 product revenue $0.6M; net loss $28.6M; SG&A elevated from CARDAMYST launch.
  • 800+ prescribers; 1,500+ CARDAMYST scripts; ~50% insured lives; Prix Galien USA nomination.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event